Naturally Splendid (TSXV:NSP) (“Naturally Splendid” or “NSE” or the “ Company” or “Naturally Splendid USA”) is pleased to provide a further update on its previously announced non-binding Letter of Intent (“LOI”) between Naturally Splendid USA Ltd. and NeutriSci International Inc. (“NeutriSci”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), together the (“Parties”).

Naturally Splendid USA and NeutriSci are pleased to announce the extension and addition of binding terms to the previously announced LOI. This new binding LOI signifies the successful completion of an agreement to produce a sublingual HempOmega® tablet using NeutriSci’s IP and technology, as well as a sublingual tablet combining HempOmega® and CBD (cannabidiol). A definitive agreement will follow in the coming weeks.


The definitive agreement will include at least two NeutriSci formulated sublingual tablets, including:

  1. a CBD/HempOmega® fortified sublingual tablet; and
  2. a HempOmega® fortified sublingual tablet.

Both parties have agreed to expand the initial scope of distribution. The newly developed HempOmega® sublingual tablet will now be available through Naturally Splendid’s partner distribution networks in South Korea, Japan and Australia.

In addition, Naturally Splendid will commence distribution of NeutriSci’s neuenergy® in the Australian market.  Neuenergy® is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products.

Production will begin on the full spectrum HempOmega® tablets to be sold in South Korea, Japan and now Australia, and will be manufactured at a licensed partner facility in Northern California. Additionally, as regulations allow, Naturally Splendid will begin marketing the CBD / HempOmega® sublingual tablets in regions where CBD (cannabidiol) products are approved for sale.

Doug Mason, CEO of Naturally Splendid commented: “This is yet another significant milestone for NSE’s proprietary HempOmega®, the micro-encapsulated hemp seed oil ingredient that continues to excel in the product formulations it was intended to enhance. We have been eagerly developing this product with NeutriSci for sale in international territories, and executing this extended LOI will accelerate our entry to these markets, as well as allow for new formulations to be launched rapidly. Accessing our already established distribution network gives NSE and NeutriSci an advantage most companies are still striving to achieve. We anticipate a swift and timely closure to the definitive agreement and will provide updates in short order. NSE would like to thank NeutriSci for their commitment and contribution to producing high-quality, innovative products, that we are excited to be co-producing.”

NeutriSci’s CEO, Glen Rehman commented, “This new arrangement brings us a final step closer to introducing and establishing a one-of-a-kind HempOmega® product into the Asian and Australian marketplace. This ground-breaking product becomes accessible to millions of potential users and sets the stage for further expansion into the region. We look forward to the continued international diversification and execution of our expansion plans as we move forward with this product and others that incorporate our technology and IP!”

About NeutriSci International Inc.

NeutriSci specializes in the innovation, production and formulation of nutraceutical products. Established in 2009, NeutriSci’s is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for neuenergy®, the Company’s natural energy and focus supplement that has at its core, the beneficial effects of blueberries.

Neuenergy® contains a unique patented combination of blueberry extract (pterostilbene) and naturally derived caffeine, and is a revolutionary energy tab designed to deliver enhanced focus and mental clarity with no sugar, no calories and no crash associated with typical energy products. To find out more about neuenergy®, please visit www.getneuenergy.com.

For more information, please visit: www.neutrisci.com.

About Naturally Splendid Enterprises Ltd.

Naturally Splendid is a biotechnology and consumer products company that is developing, producing, commercializing, and licensing an entirely new generation of plant-derived, bioactive ingredients, nutrient dense foods, and related products. Naturally Splendid is building an expanding portfolio of patents (issued and pending) and proprietary intellectual property focused on the commercial uses of industrial hemp cannabinoid compounds in a broad spectrum of applications.

For more information e-mail info@naturallysplendid.com or call Investor Relations at 604-673-9573

On Behalf of the Board of Directors
Mr. Douglas Mason
CEO, Director

Contact Information

Naturally Splendid Enterprises Ltd.
(NSP – TSX Venture; NSPDF – OTCQB; 50N Frankfurt)
#108-19100 Airport Way
Pitt Meadows, BC, V3Y 0E2
Office:  (604) 465-0548
Fax:      (604) 465-1128
E-mail: info@naturallysplendid.com
Website: www.naturallysplendid.com

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Naturally Splendid cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond Naturally Splendid’s control including, Naturally Splendid’s ability to compete with large food and beverage companies; sales of any potential products developed will be profitable; sales of shelled hemp seed will continue at existing rates or increase; the ability to complete the sales of all bulk hemp seed purchase orders; and the risk that any of the potential applications may not receive all required regulatory or legal approval. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Naturally Splendid undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Click here to connect with Naturally Splendid (TSXV:NSP) for an Investor Presentation.

Source: globenewswire.com

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less